Gaorav Gupta (@guptalabunc) 's Twitter Profile
Gaorav Gupta

@guptalabunc

Physician scientist@UNC_Lineberger Biology & biomarkers to optimize DNA-directed cancer therapy #genomeinstability #dnarepair #breastcancer #crispr #hpv #radonc

ID: 885479558778155008

calendar_today13-07-2017 12:42:33

1,1K Tweet

1,1K Followers

632 Following

Mayo Clinic Studies (@mayostudies) 's Twitter Profile Photo

We finally have a clinical trial designed specifically for men with breast cancer! Mayo Clinic Comprehensive Cancer Center and Translational Breast Cancer Research Consortium have launched TBCRC059, the #ETHANstudy, a study that may revolutionize pre-operative treatment. For more information, please call 855-776-0015 and reference TBCRC059.

We finally have a clinical trial designed specifically for men with breast cancer! <a href="/MayoCancerCare/">Mayo Clinic Comprehensive Cancer Center</a> and <a href="/TheTBCRC/">Translational Breast Cancer Research Consortium</a> have launched TBCRC059, the #ETHANstudy, a study that may revolutionize pre-operative treatment. For more information, please call 855-776-0015 and reference TBCRC059.
Henning Willers, MD, FASTRO (@henningwillers) 's Twitter Profile Photo

1/2 It is not too early to start thinking about the #RadRes2025 Meeting in beautiful #PuertoRico Sept 21-24, 2025 🌞🌴🍹🏖️ Abstract & Submission opens in 2⃣ weeks‼️ The Program is shaping up to be FANTASTIC (prelim program link below ⬇️)🔥🔥🔥

1/2 

It is not too early to start thinking about the #RadRes2025 Meeting in beautiful #PuertoRico Sept 21-24, 2025 🌞🌴🍹🏖️

Abstract &amp; Submission opens in  2⃣ weeks‼️

The Program is shaping up to be FANTASTIC (prelim program link below ⬇️)🔥🔥🔥
alex rubinsteyn (@iskander) 's Twitter Profile Photo

I think this was part of the implicit premise of the first incarnation of Hammer Lab at Mount Sinai, about a dozen of us with math/CS backgrounds ditched tech for biomedicine. And we got humbled hard: most of what we did flopped & techies don't understand experimental design.

David R. Liu (@davidrliu) 's Twitter Profile Photo

Last night I was honored to receive the 2025 #BreakthroughPrize in the Life Sciences, reflecting the efforts of many students, collaborators, doctors, and patients in labs around the world. I hope this 4-minute excerpt can inspire when science needs public support more than ever.

Duke Radiation Oncology (@dukeradonc) 's Twitter Profile Photo

We're excited to announce the appointment of Erik Sulman, MD, PhD, as the new chair of Duke #RadOnc at Duke University School of Medicine, effective 8/1. Dr. Sulman joins us from NYU Langone Health. Looking forward to welcoming him! 🔗 radonc.duke.edu/news/erik-sulm…

We're excited to announce the appointment of Erik Sulman, MD, PhD, as the new chair of Duke #RadOnc at <a href="/DukeMedSchool/">Duke University School of Medicine</a>, effective 8/1. Dr. Sulman joins us from <a href="/nyulangone/">NYU Langone Health</a>. Looking forward to welcoming him! 🔗 radonc.duke.edu/news/erik-sulm…
Henning Willers, MD, FASTRO (@henningwillers) 's Twitter Profile Photo

📢I am honored to be running alongside Sunil Krishnan & David Yu for Vice-President Elect of the Radiation Research Society 🙏🙏🙏 🧐You can find more info on the candidates here 👉 ftp.ameetingbydesign.com/ambddrop/2025%… Vote by May 1⃣3⃣🗳️ radres.org/Login.aspx

📢I am honored to be running alongside 
Sunil Krishnan &amp; David Yu 
for Vice-President Elect of the <a href="/RRS_RadRes/">Radiation Research Society</a>  🙏🙏🙏

🧐You can find more info on the candidates here 👉
ftp.ameetingbydesign.com/ambddrop/2025%…

Vote by May 1⃣3⃣🗳️ radres.org/Login.aspx
UNCmdphd (@uncmdphd) 's Twitter Profile Photo

Congratulations to our Co-Director Mohanish Deshmukh, PhD for being named William R. Kenan, Jr. Distinguished Professor!!! 👏 DeshmukhLab #unc #uncmdphd

Anshul Kundaje (anshulkundaje@bluesky) (@anshulkundaje) 's Twitter Profile Photo

Cutting STEM grants in the name of fighting anti-semitism is just an utter farce. Cutting this grant to this lab that is at the forefront of studying antibiotic resistance, an increasingly dangerous problem that threatens countless lives, is just plain insanity.

Memorial Sloan Kettering Cancer Center (@mskcancercenter) 's Twitter Profile Photo

We're excited to share that Dr. Andy Minn will return to MSK as the inaugural Chair of MSK’s new Immuno-Oncology Program in August. This is a full-circle moment for Dr. Minn, a renowned physician-scientist, who completed his postdoctoral training with Dr. Joan Massagué,

We're excited to share that Dr. Andy Minn will return to MSK as the inaugural Chair of MSK’s new Immuno-Oncology Program in August. 

This is a full-circle moment for Dr. Minn, a renowned physician-scientist, who completed his postdoctoral training with Dr. Joan Massagué,
UNC Lineberger (@unc_lineberger) 's Twitter Profile Photo

Congrats to Lisa Carey, MD, ScM, FASCO & team on receiving ARPA-H funding to lead a nat'l study developing an innovative adaptive tx platform for metastatic breast cancer that detects tumor changes, updates tx & tests tx plans. #CancerResearch The Breast Cancer Research Foundation tinyurl.com/4av9jkkt

Robert Ferris, MD, PhD (@robertferrismd) 's Twitter Profile Photo

Exciting and transformative clinical trial to drive advances in breast cancer outcomes and cures! We are proud UNC Lineberger to support Dr Carey and team of collaborators across the country to launch this important study.

ASTRO (@astro_org) 's Twitter Profile Photo

ASTRO is pleased to announce the recipients of the 2025 ASTRO Gold Medal Award. The recipients will be presented with the Gold Medal at the #ASTRO25 Annual Meeting in San Francisco. astro.org/about-astro/re… Quynh Thu Le Stanford Radiation Oncology UNC Department of Radiation Oncology

Paolo Tarantino (@ptarantinomd) 's Twitter Profile Photo

The curves everybody’s been waiting for. First line T-DXd + pertuzumab significantly prolonged PFS over THP for HER2+ MBC (40.7 vs 26.9 months, HR 0.56, p<0.001), doubled the rate of complete responses (15% vs 8%) and had a positive OS trend (HR 0.84). Practice changing data.

The curves everybody’s been waiting for. 

First line T-DXd + pertuzumab significantly prolonged PFS over THP for HER2+ MBC (40.7 vs 26.9 months, HR 0.56, p&lt;0.001), doubled the rate of complete responses (15% vs 8%) and had a positive OS trend (HR 0.84). Practice changing data.
UNCmdphd (@uncmdphd) 's Twitter Profile Photo

MD-PhD Student, Jeremy Fine, receives Impact Award for his work on improving transportation systems for North Carolina patients experiencing mental health crises! Jeremy Fine 👏 #uncmdphd #mdphd